Ayunova Pharmaceutical LLP

Artemether 20 mg + Lumefantrine 120 mg Tablets BP

Artemether + Lumefantrine Tablets BP is a fixed-dose antimalarial combination used for the treatment of uncomplicated Plasmodium falciparum malaria.

• Artemether – a fast-acting artemisinin derivative that rapidly reduces the number of malaria parasites in the blood.

• Lumefantrine – a slow-acting antimalarial that eliminates residual parasites, preventing recrudescence.

• This combination ensures high efficacy, rapid parasite clearance, and reduced resistance development.

It is widely used in malaria-endemic regions and is recommended by the World Health Organization (WHO) as a first-line therapy for uncomplicated malaria caused by P. falciparum.

Each tablet contains:

• Artemether BP/USP – 20 mg

• Lumefantrine BP/USP – 120 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Artemether + Lumefantrine Tablets are indicated for:

1. Uncomplicated Plasmodium falciparum malaria

2. Rapid parasite clearance in acute malaria episodes

3. Prevention of malaria relapse and recrudescence

4. Treatment of malaria in adults, adolescents, and children above recommended age

5. First-line therapy in areas with chloroquine-resistant P. falciparum

• Adults and children: as per body weight and standard guidelines (usually 6-dose regimen over 3 days)

• Take with a full glass of water and preferably with food or milk to enhance absorption

• Complete the entire treatment course even if symptoms improve

• Dose adjustment may be necessary in patients with hepatic impairment

• Blister packs: 6 / 12 tablets per strip

• Boxes with product information leaflet

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Artesunate 50 mg Tablets BP

Artesunate 50 mg Tablets BP is a fast-acting antimalarial drug used for the treatment of uncomplicated and severe malaria caused by Plasmodium falciparum.

• Artesunate – a water-soluble artemisinin derivative that rapidly reduces parasitemia by producing free radicals that damage parasite proteins.

• Provides rapid fever reduction and parasite clearance, making it ideal for acute malaria management.

• Commonly used in malaria-endemic regions and recommended by the World Health Organization (WHO) as a first-line therapy.

Each tablet contains:

• Artesunate BP/USP – 50 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Artesunate 50 mg Tablets are indicated for:

1. Treatment of uncomplicated P. falciparum malaria

2. Treatment of severe malaria (usually in combination with other antimalarials)

3. Rapid reduction of parasitemia and fever

4. Prevention of malaria complications and recrudescence

5. Combination therapy with other antimalarials as recommended by WHO

6. Malaria treatment in adults and children above recommended age/weight

• Adults and children: as per body weight and standard malaria treatment guidelines

• Take with a full glass of water and preferably after food to enhance absorption

• Complete the full course of therapy even if symptoms improve

• Monitor liver and renal function in severe cases

• Blister packs: 6 / 12 tablets per strip

• Boxes with product information leaflet

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Chloroquine Phosphate 250 mg Tablets BP

Chloroquine Phosphate 250 mg Tablets BP is a widely used antimalarial drug for the treatment and prevention of malaria caused by Plasmodium species.

• Chloroquine Phosphate – interferes with parasite’s ability to detoxify heme, leading to parasite death.

• Effective against uncomplicated malaria caused by P. vivax, P. ovale, and P. malariae.

• Provides rapid symptom relief, fever reduction, and parasite clearance.

• Can also be used for prophylaxis in malaria-endemic regions.

Each tablet contains:

• Chloroquine Phosphate BP/USP – 250 mg

• Excipients: Suitable tablet base, binders, fillers, and disintegrants

Chloroquine Phosphate 250 mg Tablets are indicated for:

1. Treatment of uncomplicated malaria

   • Caused by P. vivax, P. ovale, P. malariae

2. Prophylaxis of malaria

   • In travelers and residents in malaria-endemic areas

3. Treatment of extraintestinal amebiasis (off-label in some guidelines)

4. Rapid reduction of fever and parasitemia

5. Prevention of malaria complications

• Adults: Typically 600 mg base (equivalent to 1000 mg salt) initially, followed by maintenance doses as per medical guidelines

• Can be taken with or without food

• Complete the full course to ensure efficacy

• Use under medical supervision; dose adjustment may be required in renal or hepatic impairment

• Blister packs: 10 / 14 / 20 / 28 tablets per strip

• Boxes with product information leaflet

• Store below 25°C

• Protect from light and moisture

• Keep out of reach of children

Artesunate for Injection BP

Artesunate for Injection BP is a semi-synthetic derivative of artemisinin, used as a rapid-acting antimalarial agent. It is highly effective against Plasmodium falciparum and other malaria parasites, including strains resistant to conventional antimalarials.

This sterile injectable formulation ensures fast absorption and rapid parasite clearance, making it ideal for severe and complicated malaria cases. It is intended for intravenous (IV) or intramuscular (IM) administration under medical supervision.

Each vial contains:

• Artesunate BP – 60 mg / 100 mg / 120 mg

• Excipients: q.s. for sterile injection (lyophilized powder)

After reconstitution with sterile water, it is ready for IV or IM administration.

• Severe malaria caused by Plasmodium falciparum

• Complicated malaria with cerebral involvement

• Malaria with high parasitemia

• Combination therapy with other antimalarials for uncomplicated malaria

• Treatment of malaria in pregnancy (under supervision)

• Adjunct therapy in multi-drug resistant malaria regions

• Route: Intravenous (IV) or Intramuscular (IM) injection

• Adult Dose: Typically 2.4 mg/kg body weight IV/IM at 0, 12, and 24 hours, followed by once daily

• Pediatric Dose: Adjusted by body weight, same schedule as adults

• Monitoring: Parasite clearance, vital signs, and clinical response

⚠ Administer only under specialist supervision

• Available strengths: 60 mg, 100 mg, 120 mg vials

• Lyophilized powder for injection

• Hospital and bulk packaging available

• Store 2–8°C (Refrigerated)

• Protect from light and moisture

• Do not freeze

• Keep out of reach of children

Artesunate + Sulfadoxine + Pyrimethamine Tablets BP

Artesunate + Sulfadoxine + Pyrimethamine Tablets BP is a combination antimalarial therapy used for the treatment and prevention of Plasmodium falciparum malaria.

• Artesunate: A rapid-acting artemisinin derivative that kills Plasmodium parasites by generating free radicals within infected red blood cells.

• Sulfadoxine: A long-acting sulfonamide that inhibits dihydropteroate synthase, preventing folate synthesis in Plasmodium species.

• Pyrimethamine: A dihydrofolate reductase inhibitor that blocks folate metabolism, enhancing the antimalarial effect of sulfadoxine.

This triple combination therapy provides rapid parasite clearance, sustained suppression, and prevention of malaria recurrence, making it ideal for areas with chloroquine-resistant malaria.

Each tablet contains:

• Artesunate BP – 50 mg

• Sulfadoxine BP – 500 mg

• Pyrimethamine BP – 25 mg

• Excipients: q.s.

• Uncomplicated Plasmodium falciparum malaria

• Combination therapy for drug-resistant malaria

• Prevention of malaria recurrence in endemic regions

• Adjunct therapy in severe malaria cases as per physician guidance

• Treatment of mixed malaria infections

• Route: Oral

• Usual Dose: As prescribed by the physician, depending on age and weight

• Administration: Take with water, preferably after food to reduce gastrointestinal discomfort

⚠ Use with caution in patients with severe hepatic or renal impairment
⚠ Not recommended during pregnancy without medical supervision
⚠ Monitor for hypersensitivity reactions or hematologic abnormalities

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Artesunate + Mefloquine Tablets BP – 300 mg

Artesunate + Mefloquine Tablets BP is a fixed-dose combination antimalarial therapy used for the treatment of uncomplicated Plasmodium falciparum malaria, including drug-resistant strains.

• Artesunate: A fast-acting artemisinin derivative that kills malaria parasites rapidly by generating reactive free radicals inside infected red blood cells.

• Mefloquine: A long-acting antimalarial agent that inhibits parasite replication, providing sustained suppression and preventing recurrence.

This combination provides rapid parasite clearance, long-lasting protection, and high efficacy against multidrug-resistant malaria, making it ideal for endemic regions.

Each tablet contains:

• Artesunate BP – 100 mg

• Mefloquine BP – 200 mg

• Excipients: q.s.

• Uncomplicated Plasmodium falciparum malaria

• Treatment of drug-resistant malaria strains

• Prevention of malaria recurrence in endemic areas

• Part of combination therapy in multidrug-resistant malaria management

• Rapid reduction of parasitemia in adults and children (as per physician guidance)

• Route: Oral

• Usual Dose: As prescribed by the physician, based on weight and severity

• Administration: Take with water, preferably after food to minimize gastrointestinal discomfort

⚠ Use with caution in patients with a history of seizures, psychiatric disorders, or cardiac arrhythmia
⚠ Not recommended in pregnancy or lactation without medical supervision
⚠ Monitor for gastrointestinal or neuropsychiatric side effects

• Blister strips / HDPE bottles

• Retail, hospital, and export packaging available

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Hydroxychloroquine Tablet IP 200 mg is an oral antimalarial and immunomodulatory medication used in the treatment and prevention of malaria, as well as in certain autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus (SLE). It works by interfering with the growth of malaria parasites in red blood cells and modulating immune system activity. This medication should be used under the supervision of a qualified physician.

• Active Ingredient:
  Hydroxychloroquine Sulfate – 200 mg

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablet

Hydroxychloroquine Tablets are indicated for:

• Prevention and treatment of malaria

• Management of rheumatoid arthritis

• Management of systemic lupus erythematosus (SLE)

• Other conditions as prescribed by a physician

(Prescription medicine – use only under medical supervision)

• Dosage as directed by the treating physician

• Tablets should be swallowed whole with water

• Can be taken with or after food to reduce gastrointestinal irritation

• Regular monitoring may be required for long-term use

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Use with caution in patients with liver or kidney impairment

• Long-term use may require eye examination due to risk of retinopathy

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

• Manufactured in compliance with IP and GMP guidelines

• Quality tested for safety, purity, and efficacy

• India

Hydroxychloroquine Tablets 300 mg is an oral antimalarial and immunomodulatory medication used for the treatment and prevention of malaria, as well as in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus (SLE). It works by inhibiting the growth of malaria parasites in red blood cells and modulating immune system activity. This medicine should be used under the supervision of a qualified healthcare professional.

• Active Ingredient:
  Hydroxychloroquine Sulfate – 300 mg

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablet

Hydroxychloroquine Tablets 300 mg are indicated for:

• Prevention and treatment of malaria

• Management of rheumatoid arthritis

• Management of systemic lupus erythematosus (SLE)

• Other conditions as prescribed by a physician

(Prescription medicine – use only under medical supervision)

• Dosage as directed by the treating physician

• Tablets should be swallowed whole with water

• Can be taken with or after food to reduce gastrointestinal irritation

• Regular monitoring may be required during long-term therapy

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Use with caution in patients with liver or kidney impairment

• Long-term therapy may require periodic eye examinations due to risk of retinopathy

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

• Manufactured in compliance with IP and GMP guidelines

• Quality tested for safety, purity, and efficacy

• India

Hydroxychloroquine Tablets IP 400 mg is an oral antimalarial and immunomodulatory medication used for the treatment and prevention of malaria and in certain autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus (SLE). It works by inhibiting the growth of malaria parasites in red blood cells and modulating immune responses. This medicine should be used under the supervision of a qualified healthcare professional.

• Active Ingredient:
  Hydroxychloroquine Sulfate – 400 mg

• Excipients:
  q.s.

• Dosage Form:
  Film-coated tablet

Hydroxychloroquine Tablets 400 mg are indicated for:

• Prevention and treatment of malaria

• Management of rheumatoid arthritis

• Management of systemic lupus erythematosus (SLE)

• Other conditions as prescribed by a physician

(Prescription medicine – use only under medical supervision)

• Dosage as directed by the treating physician

• Tablets should be swallowed whole with water

• Can be taken with or after food to reduce gastrointestinal irritation

• Regular monitoring may be required during long-term therapy

• Store below 30°C

• Protect from moisture and direct sunlight

• Keep out of reach of children

• For prescription use only

• Not recommended during pregnancy or breastfeeding unless prescribed

• Use with caution in patients with liver or kidney impairment

• Long-term therapy may require periodic eye examinations due to risk of retinopathy

• Strip or bottle packing (as available)

• Suitable for hospital and pharmacy supply

• Manufactured in compliance with IP and GMP guidelines

• Quality tested for safety, purity, and efficacy

• India